Lululemon sues Costco, alleging the retailer copied its designs
In a lawsuit filed Friday in the U.S. District Court for the Central District of California, the athletic and lifestyle apparel company claims that certain Costco products imitate its own designs so closely that it constitutes "trade dress" infringement, which occurs when a product mimics another so closely that it confuses consumers.
The apparel company claims that Costco's "knockoff" designs, or product "dupes," violate trademark law because "some customers incorrectly believe these infringing products are authentic Lululemon apparel." In other cases, "customers specifically purchase the infringing products because they are difficult to distinguish from authentic Lululemon products," the lawsuit alleges.
"Indeed, one of the purposes of selling 'dupes' is to confuse consumers at the point-of-sale and/or observers post-sale into believing that the 'dupes' are Plaintiffs' authentic products when they are not," the lawsuit alleges.
Lululemon refers to itself in the lawsuit as a "path-breaking" apparel company that has set a new standard for performance athletic wear, adding that its "construction techniques" and "strategic fits" help it stand out to consumers. Reached for comment, the Vancouver, Canada-based company said it fiercely defends its products.
"As an innovation-led company that invests significantly in the research, development and design of our products, we take the responsibility of protecting and enforcing our intellectual property rights very seriously and pursue the appropriate legal action when necessary," a Lululemon company spokesperson told CBS MoneyWatch.
Costco did not immediately respond to CBS MoneyWatch's request for comment.
While copycat products can be so poorly constructed and designed that they pose no threat to the originals, Costco's dupes have caused a stir for their verisimilitude to the authentic Lululemon goods. A January headline in The Washington Post read, "Is that hoodie Lululemon or a Costco dupe? No one has to know but you." On social media, users post images and videos of Costco athletic-wear products with the hashtag #luludupe or #lululemondupes.
What items does Lululemon say Costco copies?
The items at the center of the lawsuit include Lululemon's popular "Scuba" hoodies and sweatshirts, its "Define" jackets, and "ABC" stretch pants — that resemble khakis pants — for men.
Lululemon's Scuba hoodie retails for $118, while its Define jacket sells for $128. The ABC pants cost $128.
According to Lululemon, Costco's infringing products include:
Danskin Ladies Half-Zip Hoodie
Danskin Half-Zip Pullover
Jockey Ladies Yoga Jacket
Spyder Women's Yoga Jacket
Hi-Tec Men's Scuba Full Zip
Kirkland 5 Pocket Performance Pant
Lululemon is seeking damages in the form of lost profits, and for Costco to cease the manufacturing and distribution of products Lululemon claims violate trade dress.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
19 minutes ago
- Bloomberg
Vitol Launches Mine Finance Fund as Competition Grows for Metals
Vitol Group and Breakwall Capital have formed a credit fund targeting mining companies in the Americas, as competition among traders for copper and other metals contracts heats up. Valor Mining Credit Partners LP will be managed by Breakwall and offer capital to companies looking to refinance debt, make acquisitions and expand in other ways, the firms said. Breakwall, which spun out from Riverstone Credit Partners last year, already partners with Vitol on another fund focused on upstream oil and gas.
Business Insider
24 minutes ago
- Business Insider
ELD Asset Management Launches Smart Workspaces
ELD Asset Management Introduces AI-Powered Smart Workspaces to Drive Sustainability, Enhance Collaboration, and Elevate Employee Well-being ELD Asset Management, a Singapore-based investment and wealth management firm, has announced significant upgrades to its offices, introducing advanced smart workspace technology designed to enhance employee collaboration, sustainability, and operational efficiency. This strategic initiative aligns with growing global interest in adaptive work environments, with the smart workspace market projected to reach USD 33.09 billion by 2029. ELD offices are now equipped with IoT-enabled sensors and automated management systems, achieving energy savings of up to 70% within three years. Employee productivity has also improved notably, with 72% of staff reporting streamlined task management through smart automation. The company's investment in smart workspace solutions reflects its commitment to sustainability and operational efficiency, aiming to enhance employee experiences by providing tailored work environments that support improved daily operations and productivity. Advanced technologies introduced by ELD Asset Management include automated systems for personalised lighting, temperature control, and ergonomic workspace configurations, aligning with individual preferences through sophisticated AI-driven adjustments. Wearable devices that monitor stress indicators, such as heart rate variability and skin temperature, have also been implemented, actively promoting employee well-being. Additionally, ergonomic assessments leveraging computer vision technology have successfully reduced workplace injuries by up to 68%. Collaboration across hybrid work environments has significantly improved through intelligent meeting room systems equipped with advanced audio-visual technology. Automated transcription, summarisation, and scheduling tools have reduced administrative burdens and facilitated seamless communication across popular platforms like Microsoft Teams and Slack. The scalability and security of these workspace enhancements ensure long-term operational agility. Real-time analytics optimise resource allocation, and enhanced security systems substantially improve threat detection capabilities. The firm views smart workspace technology as a core component in maintaining its competitive edge, noting that it plays a critical role in supporting its growth strategy through the delivery of scalable, secure, and responsive office environments. ELD Asset Management's adoption of these advanced solutions exemplifies its ongoing commitment to innovation, employee satisfaction, and environmental responsibility. Established in 2017, ELD Asset Management Pte. Ltd. (UEN: 201725839Z) offers strategic investment advisory services informed by rigorous market analysis and global economic insights, enabling clients to capitalise on emerging opportunities.
New York Post
24 minutes ago
- New York Post
Pfizer scientist subpoenaed over claims COVID vax testing was ‘deliberately' slowed before 2020 election
WASHINGTON — A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that senior executives at the pharma giant colluded to 'deliberately slow down' clinical tests of its COVID-19 vaccine ahead of the 2020 presidential election. The House Judiciary Committee ordered Dr. Philip Dormitzer, the ex-vice president and chief scientific officer of RNA and viral vaccines for Pfizer, to appear for a deposition on July 22 after demanding answers about allegations 'that senior Pfizer executives conspired to withhold public health information so as to influence the 2020 presidential election.' 'To date, you have failed to voluntarily comply with our requests,' wrote Judiciary Chairman Jim Jordan (R-Ohio). 'Therefore, the Committee must resort to compulsory process to obtain your testimony and the requested documents.' 4 The House Judiciary Committee ordered Dr. Philip Dormitzer, the ex-vice president and chief scientific officer of RNA and viral vaccines for Pfizer, to appear for a deposition on July 22. Bloomberg via Getty Images In a May 29 letter to the Judiciary panel, Dormitzer attorney Susan Brune indicated that her client did not have any relevant records and promised 'Pfizer's representatives are or will be in communication … to provide whatever details you might request.' Jordan's panel wrote to Pfizer's chairman and CEO, Dr. Albert Bourla, in May asking for emails, texts, meeting notes and other documents showing any data from the clinical trials or communications with federal public health agencies. Brune and reps for Pfizer did not immediately respond to requests for comment. 4 Dormitzer has previously denied that he or anyone at Pfizer tried to delay the vaccine. Getty Images The London-based drugmaker GSK had first revealed the purported conspiracy to Jordan in an April 16 letter, claiming that Dormitzer had asked to be relocated outside the US in November 2024 'due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine.' Asked why he wanted to move, Dormitzer told the GSK employee: 'Let's just say it wasn't a coincidence, the timing of the vaccine.' Dormitzer also disclosed to other GSK employees 'in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year,' according to the letter to Jordan. 4 Pfizer's COVID vaccine results, first reviewed by independent experts for effectiveness and safety, were shared by its team of scientists just five days after polls closed for the 2020 election on Nov. 3. REUTERS Notably, GSK denied that Dormitzer was admitting to intentionally 'delaying disclosure of completed results,' but described it as 'a situation of slowing down results before disclosure became necessary.' Pfizer's COVID vaccine results, first reviewed by independent experts for effectiveness and safety, were shared by its team of scientists just five days after polls closed for the 2020 election on Nov. 3. Media outlets called the race for former President Joe Biden on Nov. 7. Dormitzer has previously denied that he or anyone at Pfizer tried to delay the vaccine rollout, and said his comments to his colleagues at GSK have been misinterpreted. 4 The London-based drugmaker GSK claimed that Dormitzer had asked to be relocated outside the US in November 2024 'due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine.' REUTERS Dormitzer has only donated to Democratic campaigns, Federal Election Commission (FEC) filings show, shelling out hundreds of dollars in the 2010s to congressional candidates while working in vaccine development at Novartis. Manhattan prosecutors first unearthed the bombshell allegations about the vaccine trials as part of a federal investigation into Pfizer. 'The COVID-19 vaccine development process was driven by science and guided by the U.S. FDA back in 2020,' a rep for the company previously said in a statement. 'We have consistently and transparently reiterated the facts and the timeline of the tireless work of scientists, regulators, and thousands of clinical trial volunteers who made the vaccine possible. Theories to the contrary are simply untrue and being manufactured.'
